bioAffinity Technologies announced a record monthly testing volume for its CyPath Lung test in October 2026, with 235 tests performed. This volume represents a 29% increase over October 2025 and is equivalent to approximately 45% of the total tests performed in the entire third quarter of 2026. The company attributed the growth to expanded sales efforts and increased adoption by both new and existing physicians.
bioAffinity Technologies announced it will participate in the Lung Cancer Initiative of North Carolina’s 'Battle of the Blues' event on November 5, 2026. The company will highlight its CyPath Lung noninvasive diagnostic test alongside physicians and patient advocates to promote early lung cancer detection during National Lung Cancer Awareness Month.
bioAffinity Technologies reported that sales of its CyPath Lung test increased more than 100% through the third quarter of 2026 compared to 2025. The company delivered 1,620 tests through Q3 2026, driven by an 89% increase in the number of ordering physician offices and expanded utilization by existing customers.
bioAffinity Technologies and its distribution partner AvMEDICAL debuted their joint exhibition of the CyPath Lung cancer test at the NAVREF 2026 Annual Conference. The update highlights progress under a previously announced distribution agreement aimed at expanding veteran access to noninvasive lung cancer testing through federal procurement channels.